This histogram enumerates side effects from a completed 2020 Phase 3 trial (NCT03500549) in the Open-label Period: Pegcetacoplan ARM group. Side effects include: Haemolysis with 17%, Nasopharyngitis with 16%, Diarrhoea with 14%, Injection site erythema with 12%, Cough with 12%.
1 Treatment Group
1 of 1
12 Total Participants · 1 Treatment Group
Primary Treatment: Pegcetacoplan · No Placebo Group · Phase 2
Experimental Group · 1 Intervention: Pegcetacoplan · Intervention Types: Drug
Drug Approval Stage
How many patients have taken this drug
Screening: ~3 weeks
Reporting: from treatment start to end of study, an average of 6 months
Who is running the clinical trial?
Apellis Pharmaceuticals, Inc.Industry Sponsor
21 Previous Clinical Trials
3,504 Total Patients Enrolled
Swedish Orphan BiovitrumLead Sponsor
79 Previous Clinical Trials
11,458 Total Patients Enrolled
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
Note: Postmenopausal is defined as having had 12 consecutive months with no menses without an alternative medical cause.
You have received allogeneic HSCT.
You have a diagnosis of TA-TMA, as per laboratory markers indicating TMA.
You have a diagnosis of TA-TMA that persists despite initial management of any triggering condition.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.